PT - JOURNAL ARTICLE AU - Nicolelis, Miguel A.L. AU - Raimundo, Rafael L. G. AU - Peixoto, Pedro S. AU - de Andreazzi, Cecília S. TI - How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil AID - 10.1101/2020.09.19.20197749 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.19.20197749 4099 - http://medrxiv.org/content/early/2020/09/20/2020.09.19.20197749.short 4100 - http://medrxiv.org/content/early/2020/09/20/2020.09.19.20197749.full AB - Although its international airports served as the country’s main entry points for SARS-CoV-2, the factors driving the uneven geographic spread of COVID-19 cases and deaths in Brazil remain largely unknown. Here we show that four major factors likely accounted for the entire dynamics of COVID-19 in Brazil. Mathematical modeling revealed that, initially, the “super-spreading city” of São Paulo accounted for roughly 80% of the case spread in the entire country. During the first 3 months of the epidemic, by adding only 16 other spreading cities, we accounted for 98-99% of the cases reported in Brazil at the time. Moreover, 26 of the major Brazilian federal highways accounted for about 30% of SARS-CoV-2’s case spread. As cases accumulated rapidly in the Brazilian countryside, the distribution of COVID-19 deaths began to correlate with a third parameter: the geographic distribution of the country’s hospital intensive care unit (ICU) beds, which is highly skewed towards state capitals where the epidemic began. That meant that severely ill patients living in the countryside had to be transported to state capitals to access ICU beds where they often died, creating a “boomerang effect” that contributed to the skew of the geographic distribution of COVID-19 deaths. Finally, we discovered that the geographic distribution of dengue fever, amounting to more than 3.5 million cases from January 2019 to July 2020, was highly complementary to that of COVID-19. This was confirmed by the identification of significant negative correlations between COVID-19’s incidence, infection growth rate, and mortality to the percentage of people with antibody (IgM) levels for dengue fever in each of the country’s states. No such correlations were observed when IgM data for chikungunya virus, which is transmitted by the same mosquito vector as dengue, was used. Thus, states in which a large fraction of the population had contracted dengue fever in 2019-2020 reported lower COVID-19 cases and deaths, and took longer to reach exponential community transmission, due to slower SARS-CoV-2 infection growth rates. This inverse correlation between COVID-19 and dengue fever was further observed in a sample of countries around Asia and Latin America, as well as in islands in the Pacific and Indian Oceans. This striking finding raises the intriguing possibility of an immunological cross-reactivity between DENV serotypes and SARS-CoV-2. If proven correct, this hypothesis could mean that dengue infection or immunization with an efficacious and safe dengue vaccine could produce some level of immunological protection for SARS-CoV-2, before a vaccine for SARS-CoV-2 becomes available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMALN was supported by a Duke University Medical Center Distinguished Professor Endowed Chair. CSA and RLGR were supported by the Brazilian Synthesis Center on Biodiversity and Ecosystem Services (SinBiose/CNPQ). PP was supported by a research grant from Fundação de Amparo &agrav Pesquisa do Estado de São Paulo (FAPESP 16/18445-7).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB and/or ethics committee approvals do not apply to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets used in this study are publicly available and the references or links to the data sources are provided in the text.